Our scientists have significant exposure to all major therapeutic areas. From a bioanalytical viewpoint, we see ourselves as therapeutic area agnostic,as we routinely analyze drug samples from any of them with minimal adjustments to our equipment and processes. That said, we are increasingly focusing more on oncology to align our interests with the demands of our current and prospective clients. Within oncology, we see a tremendous opportunity for innovation and efficiency in the drug development process,leading to higher R&D productivity and ultimately increased access to life-saving / prolonging drugs for millions of patients. To that end, our team has excellent name recognition among all premier Oncology centers in the US including, Dana Farber, MD Anderson, Sarah Cannon, Sloan Kettering, Moffitt Cancer Center, and Yale Cancer Center etc.